Literature DB >> 8548402

Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?

T Zielinski1, D Zeitter, S Müller, R R Bartlett.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8548402     DOI： 10.1007/bf01778336

Source DB:  PubMed          Journal:  Inflamm Res        ISSN： 1023-3830            Impact factor:   4.575


× No keyword cloud information.
  6 in total

1.  Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s).

Authors:  D A Carson; J Kaye; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

2.  Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent.

Authors:  C C Küchle; G H Thoenes; K H Langer; H U Schorlemmer; R R Bartlett; R Schleyerbach
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 3.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

4.  Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism.

Authors:  A Cohen; J Barankiewicz; H M Lederman; E W Gelfand
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

5.  Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.

Authors:  T Zielinski; H J Müller; R R Bartlett
Journal:  Agents Actions       Date:  1993

6.  Leflunomide and cyclosporin-A prolong fish-to-mouse islet xenograft survival in BALB/C mice.

Authors:  J R Wright; H Kearns; A S McDonald
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066
  6 in total
  5 in total

1.  Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.

Authors:  K Thoss; S Henzgen; P K Petrow; D Katenkamp; R Brauer
Journal:  Inflamm Res       Date:  1996-02       Impact factor: 4.575

Review 2.  A review of immunologic diseases of the dog.

Authors:  N C Pedersen
Journal:  Vet Immunol Immunopathol       Date:  1999-08-02       Impact factor: 2.046

3.  Leflunomide, a novel immunomodulating drug, inhibits homotypic adhesion of peripheral blood and synovial fluid mononuclear cells in rheumatoid arthritis.

Authors:  M Dimitrijevic; R R Bartlett
Journal:  Inflamm Res       Date:  1996-11       Impact factor: 4.575

4.  The mammalian homologue of Prp16p is overexpressed in a cell line tolerant to Leflunomide, a new immunoregulatory drug effective against rheumatoid arthritis.

Authors:  D Ortlepp; B Laggerbauer; S Müllner; T Achsel; B Kirschbaum; R Lührmann
Journal:  RNA       Date:  1998-08       Impact factor: 4.942

5.  Integrated, multicohort analysis reveals unified signature of systemic lupus erythematosus.

Authors:  Winston A Haynes; D James Haddon; Vivian K Diep; Avani Khatri; Erika Bongen; Gloria Yiu; Imelda Balboni; Christopher R Bolen; Rong Mao; Paul J Utz; Purvesh Khatri
Journal:  JCI Insight       Date:  2020-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.